⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758510 | 0.78 | — | — | |
| SCHEMBL4328588 | 0.74 | L3MBTL1 (0.39) | — | |
| SCHEMBL2177927 | 0.67 | — | — | |
| SCHEMBL2177635 | 0.67 | — | — | |
| SCHEMBL11551386 | 0.67 | HCAR2 (0.30) | — | |
| SCHEMBL20051932 | 0.67 | — | — | |
| SCHEMBL233044 | 0.67 | — | — | |
| SCHEMBL2179429 | 0.66 | — | — | |
| SCHEMBL422266 | 0.65 | — | — | |
| SCHEMBL830410 | 0.65 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621209-B | 1,2, 3-Thiadiazole acetonitrile derivatives, and preparation method and application thereof | 南开大学 | 2024-06-14 | — | — | CN | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| CN-114656462-B | N-containing heterocyclic aromatic hydrazone derivatives, and preparation method and application thereof | 南开大学 | 2023-12-19 | — | — | CN | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116134016-A | Tricyclic heterocycles | 默克专利股份公司 | 2023-05-16 | — | — | CN | claimed |
| CN-1252068-C | Heteroaryl derivatives as superior ligands for the nociceptin receptor ORL-1 | SCHERING CORP (US) | 2006-04-19 | — | — | CN | claimed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | claimed |
| EP-1442036-B1 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORP (US) | 2006-01-11 | — | — | EP | claimed |
| CN-1582288-A | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORP (US) | 2005-02-16 | — | — | CN | claimed |
| EP-1458683-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | claimed |
| EP-1442036-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | claimed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | claimed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |